General Biologics initiates participation in the MassBio Drive program, an accelerator designed to advance breakthrough science in Massachusetts, while providing opportunities to innovators from all parts of the life sciences ecosystem
General Biologics is the first company to move into Harvard Medical School’s Blavatnik Life Lab, a new incubator space
STTR Phase II award for “Patterned, Responsive Cellular Therapies Using Novel Mammalian Cellular Regulator Systems”
General Biologics exclusively licenses red blood cell binding technology for therapeutic development
Phase I award from DARPA: “Patterned, Responsive Cellular Therapies Using Novel Mammalian Cellular Regulator Systems”